This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer

This study has been withdrawn prior to enrollment.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: October 12, 2005
Last updated: May 29, 2013
Last verified: July 2006

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving drugs directly into the arteries around the tumor may kill more tumor cells. Giving chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether surgery and hepatic arterial chemotherapy are more effective than surgery alone in treating patients with liver cancer that has spread to the portal vein.

PURPOSE: This randomized phase III trial is studying surgery and hepatic arterial chemotherapy to see how well they work compared to surgery alone in treating patients with liver cancer that has spread to the portal vein.

Condition Intervention Phase
Localized Resectable Adult Primary Liver Cancer Stage III Childhood Liver Cancer Drug: cisplatin Drug: fluorouracil Procedure: adjuvant therapy Procedure: chemotherapy Procedure: conventional surgery Procedure: hepatic arterial infusion Procedure: surgery Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase III Randomized Study of Surgical Resection With Versus Without Postoperative Hepatic Arterial Chemotherapy in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Enrollment: 0
Detailed Description:


  • Compare the efficacy of surgical resection with vs without postoperative hepatic arterial chemotherapy in patients with hepatocellular carcinoma and portal vein tumor thrombus.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to grade of portal invasion and Child-Pugh classification. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo macroscopic curative resection. Within 28 days after surgery, patients without post-surgery complications undergo hepatic arterial infusion comprising fluorouracil and cisplatin on days 1-5, 8-12, and 15-19. Treatment continues for 6 months.
  • Arm II: Patients undergo macroscopic curative resection.

PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this study.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed hepatocellular carcinoma (HCC) with portal vein tumor thrombus
  • Tumor thrombus in the main trunk or first branch of the portal vein
  • No apparent distant metastases on chest CT scan and bone scintigraphy within the past 6 weeks
  • No pleural effusion or ascites



  • Not specified

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Neutrophil count > 1,000/mm^3
  • Platelet count > 50,000/mm^3
  • Hemoglobin > 8 g/dL


  • Bilirubin < 2 times upper limit of normal (ULN)
  • ALT and AST < 4 times ULN


  • Creatinine normal


  • No severe heart disease
  • No cardiac effusion


  • No other malignant disease
  • No high risk for esophageal varices rupture
  • No allergy to fluorouracil or cisplatin


Biologic therapy

  • Not specified


  • No prior hepatic arterial chemotherapy
  • No prior systemic chemotherapy for HCC

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00238160

Kyoto Prefectural University of Medicine
Kyoto, Japan, 602-8566
Kyoto City Hospital
Kyoto, Japan, 604-8845
Kyoto University Hospital
Kyoto, Japan, 606-8501
Kyoto-Katsura Hospital
Kyoto, Japan, 615-8256
Sponsors and Collaborators
Kyoto University
Study Chair: Iwao Ikai, MD Kyoto University
  More Information Identifier: NCT00238160     History of Changes
Other Study ID Numbers: KYUH-UHA-HCC02-01
CDR0000363800 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: October 12, 2005
Last Updated: May 29, 2013

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017